Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

WithdrawnPhase 1/2

NCT02113891

Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation

Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficie…

Location not specified0Started 2015-02

Treatment: Eculizumab

TerminatedEarly Phase 1

NCT03380936

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mi…

United States4 participantsStarted 2018-01-17

Treatment: Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )